<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Summary of the completed clinical trials of repurposed drugs for treatment of COVID-19.</p>
 </caption>
 <alt-text id="al0025">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center">Sr. no</th>
    <th align="center">Drug name</th>
    <th align="center">Target/rationale for use</th>
    <th align="center">Clinical phase (sample size)</th>
    <th align="center">Findings</th>
    <th align="center">Status</th>
    <th align="center">Clinical trial identifier</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1.</td>
    <td>Hydroxychloroquine</td>
    <td align="center">Block viral entry by inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification.
     <break/>
     <break/>Additionally, may provide immunomodulatory effects through inhibition of cytokine production, autophagy, and lysosomal activity in host cell.
    </td>
    <td align="center">Phase 3
     <break/>(30)
    </td>
    <td>No Result Posted for this study</td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04261517" id="ir0005" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04261517</ext-link>
    </td>
   </tr>
   <tr>
    <td>2.</td>
    <td>Lopinavir/ritonavir
     <break/>Ribavirin
     <break/>Interferon Beta-1B
    </td>
    <td align="center">Protease Inhibitor</td>
    <td align="center">Phase II
     <break/>(127)
    </td>
    <td>No Result Posted for this study</td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276688" id="ir0010" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04276688</ext-link>
    </td>
   </tr>
   <tr>
    <td>3.</td>
    <td>Hydroxychloroquine
     <break/>Lopinavir/Ritonavir Interferon Beta-1A Interferon Beta-1B
    </td>
    <td align="center">
     <break/>Protease Inhibitor
    </td>
    <td align="center">Phase IV
     <break/>(60)
    </td>
    <td>No Result Posted for this study
     <break/>
    </td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04343768" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04343768</ext-link>
    </td>
   </tr>
   <tr>
    <td>4.</td>
    <td>Baricitinib</td>
    <td>Anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2 that inhibits JAK1- and JAK2-mediated cytokine release</td>
    <td align="center">Phase 2 &amp; Phase 3
     <break/>(12)
    </td>
    <td>No Result Posted for this study
     <break/>
    </td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04358614" id="ir0020" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04358614</ext-link>
    </td>
   </tr>
   <tr>
    <td>5.</td>
    <td>Ganovo
     <break/>Ritonavir
     <break/>Interferon nebulization
    </td>
    <td>Hepatitis C virus protease inhibitor</td>
    <td align="center">Phase IV
     <break/>(11)
    </td>
    <td>No Result Posted for this study
     <break/>
    </td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04291729" id="ir0025" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04291729</ext-link>
    </td>
   </tr>
   <tr>
    <td>6.</td>
    <td>Methylprednisolone</td>
    <td>Immunomodulatory effect</td>
    <td align="center">Phase 2 &amp; Phase 3
     <break/>(80)
    </td>
    <td>No Result Posted for this study</td>
    <td>Completed</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04244591" id="ir0030" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04244591</ext-link>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
